NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

What do you think about the NICE incentive that seemingly places companies in the strange position to leave their OS blinded longer in order to get more monetary valuation on their product? How would they make a fair determination when a crossover is in play? What historical precedence, concurrent or post approval results, if any, could they instead use in order to get these products to market instead of potentially forcing companies to pad results. Can market price be increased if commercial data demonstrates additional longevity? Finally, why does a company like AZN, in their most important MYSTIC trial, believe they can unveil PFS ahead of OS. Other than market confidence, what advantage does it bring them?